Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 18 Carcinoma, Non-Small-Cell Lung 10 Carcinoma, Renal Cell 9 Kidney Neoplasms 4 Stomach Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Diabetes Mellitus, Insulin-Dependent, 12 3 Carcinoma, Hepatocellular 3 Skin Neoplasms 2 Prostatic Neoplasms 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Neoplasm Metastasis 2 Mesothelioma, Malignant 2 Head and Neck Neoplasms 2 Colorectal Neoplasms 2 Various Advanced Cancer 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Recurrent Squamous Cell Lung Carcinoma 1 Recurrence 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Melanoma, Cutaneous Malignant 1 Lymphatic Metastasis 1

Interventions

Nivolumab 2 Ipilimumab 1 Fluorouracil 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Various Advanced Cancer × Ipilimumab × Clear all

NCT03143153 2026-02-17

CheckMate 648

Bristol-Myers Squibb

Phase 3 Completed

970 enrolled 15 charts 1 FDA

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡